Despite MERS sales of listed pharmaceutical companies increased 10% up in the 2nd quarter
Despite the Middle East Respiratory Syndrome, which struck Korea in the 2nd quarter of the year, sales of listed pharmaceutical companies are assessed to be decent.
According to the analysis result of sales reports of 58 KOSPI and KOSDAQ listed pharmaceutical companies in the 2nd quarter of the ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
